it is assumed the income from other uses of ACR's drug delivery...

it is assumed the income from other uses of ACR's drug delivery technology is not much compared with Axiron income

What are they doing with the rest of the pipeline? What's happening with the existing products? New partnerships? Heck, they have enough money to fund their own trials.

Axiron has been a bigger success than I'd hoped for, but the reason I bought into Acrux was the depth of its product pipeline and the likelihood that one successful product would validate the technology and unlock the floodgates to more.

Management appear to have given up on R&D since the Eli Lilly deal and to be sitting on their hands waiting for a takeover.